Lakefront Biotherapeutics (GLPGF) Total Debt (2020)
Lakefront Biotherapeutics' (GLPGF) quarterly Total Debt came in at $83460.3 in Q4 2020.
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) Total Debt (2020) Analysis & Trends
Lakefront Biotherapeutics (GLPGF) has reported Total Debt for 1 consecutive years, with $83460.3 the latest figure, recorded in Q4 2020.
- On a quarterly basis, Total Debt changed N/A year-over-year to $83460.3 in Q4 2020; TTM through Dec 2020 was $83460.3, a N/A change from a year earlier, with the FY2020 full-year figure at $83460.3, changed N/A from the prior year.
- Total Debt was $83460.3 for Q4 2020 at Lakefront Biotherapeutics.
- Over five years, Total Debt peaked at $83460.3 in Q4 2020 and troughed at $83460.3 in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.37 Bn | 197.38 Bn | 7.24 Bn | 62.75 Bn |
| 2 | Gilead Sciences | 181.12 Bn | 177.94 Bn | 6.22 Bn | 28.66 Bn |
| 3 | Vertex Pharmaceuticals | 132.11 Bn | 124.26 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.51 Bn | 74.52 Bn | 3.93 Bn | 1.99 Bn |
| 5 | Argenx Se | 61.69 Bn | 56.50 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.62 Bn | 49.48 Bn | 52.00 Mn | 591.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.14 Bn | 30.84 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.29 Bn | 30.01 Bn | 1.96 Bn | 8.09 Bn |
| 9 | Roivant Sciences | 30.09 Bn | 30.09 Bn | 1.16 Mn | - |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn | - |